Pediatric Dermatology

Diagnosis, risk assessment and treatment of congenital melanocytic nevi (CMN), as well as melanoma, require specific strategies for pediatric patients.

With up to 30% of pediatric health care visits involving skin complaints and fewer than 400 board-certified pediatric dermatologists in the United States, teledermatology offers a valuable tool for increasing access and cutting wait times.

Spending time around animals as an infant has been suggested as a way to reduce the incidence of atopic dermatitis. An investigation offers some insight.

While Mohs micrographic surgery is well established as a safe and effective therapeutic modality in adult patients, it is not as commonly used in pediatric populations. There are unique challenges to performing Mohs surgery on pediatric patients, especially with patient cooperation. Multidisciplinary planning may be needed.

Infants with eczema may require different approaches to preventing food allergies, including early introduction of peanuts to increase oral exposure to allergens before skin exposure.

In a recent phase 3 trial, dupilumab (Dupixent, Sanofi and Regeneron) demonstrated positive results in itch reduction, skin clearance and quality-of-life. Indicating the biologic as a viable treatment option for severe atopic dermatitis in younger children.

The U.S. FDA has approved to expand the indication for golimumab (SIMPONI ARIA, Janssen Pharmaceutical Companies of Johnson & Johnson) to include it was a treatment for active psoriatic arthritis (PsA) in pediatric patients 2 years and older.

In the final part of our interview with Candrice Heath, M.D., she discusses some of the treatment challenges associated with treating pediatric patients with skin of color and how to overcome these obstacles.

In part two of our interview with Candrice Heath, M.D., she explains the most commonly encountered skin conditions when treating young skin of color patients.

Candrice Heath, M.D., shares her tips and tricks for treating young skin of color patients from her presentation at the 2020 Skin of Color Update.

A recent article suggests physicians should be on the lookout for various dermatologic manifestations in pediatric patients suspected of having COVID-19.

In this episode, Candrice Heath, M.D., sits down to discuss her recent presentation at the 2020 Skin of Color Update about clinical pearls for kids, tweens and teens with skin of color. Dr. Heath also explains the most common skin conditions for this patient group, treatment challenges, and much more.

This episode discusses how to become a pediatric dermatologist, including the associated benefits, compensation and responsibilities with Heather Brandling-Bennett, M.D.

The U.S. Food and Drug Administration has approved IL-12/IL-23 inhibitor ustekinumab (Stelara, Janssen Pharmaceutical Companies of Johnson & Johnson) for treatment of moderate-to-severe plaque psoriasis in pediatric patients 6-11 years.

The European Commission has approved secukinumab (Cosentyx, Novartis) for treatment of moderate-to-severe plaque psoriasis in pediatric patients 6<18 years in the European Union.

Gain insight from the experts on current and future treatment for pediatric atopic dermatitis.

The Society of Pediatric Dermatology introduces a new president and executive committee for 2020-2021 during their virtual 45th Annual Meeting.

The Inaugural Pediatric Dermatology 2020: Best Practices and Innovations Conference is now open for registration and scheduled to take place June 27th, offering seven free CME credits.

The FDA announced it has accepted a priority review of dupilumab for the treatment of moderate-to-severe AD in pediatric patients 6 to 11 years of age. The drug is already approved for treatment of AD in adolescents and adults.

Atopic dermatitis presents differently depending on whether the patient is an adult or child. This means that different treatments may be more effective in an adult than children and vice versa. 

Weight-based dosing of apremilast appeared to ensure comparable efficacy, safety and tolerability with in kids as in adults, and should be explored in future studies.

About one-third of patients with psoriasis are children or adolescents. Still, little research exists on treating this patient population. New disease management guidelines and emerging studies seek to fill the gap.

Crisaborole ointment, 2%, (Eucrisa, Pfizer) appears to be safe and effective in children aged three months to less than 24 months who have mild-to-moderate atopic dermatitis, according to results of a phase 4 trial released yesterday.

Pulsed dye laser (PDL) is widely accepted as the gold standard treatment of port-wine stains (PWS), but how early can you begin treating infants with PWS? According to this expert and a recent study, the sooner the better.